<?xml version="1.0" encoding="utf-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:og="http://ogp.me/ns#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:schema="http://schema.org/" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" version="2.0" xml:base="http://www.cdti.es/en">
<channel>
<title>INNVIERTE</title>
<link>http://www.cdti.es/en</link>
<description/>
<language>en</language>
<item>
<title>El CDTI Innovación y Suma Capital invierten en WATTWIN, la plataforma que digitaliza los servicios de venta de proyectos fotovoltaicos</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-y-suma-capital-invierten-en-wattwin-la-plataforma-que-digitaliza-los</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The Innovation and CDTI Suma Capital invested in WATTWIN, the platform which digitizes the sales of photovoltaic project</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Thu, 02/27/2025 - 12:10</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-02-21T12:00:00Z" class="datetime">21 February 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The Innovation and CDTI Suma Capital invested in WATTWIN, the platform which digitizes the sales of photovoltaic project</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI innovation, through its programme invests and jointly with Suma Capital, through its merits SC ENION I ENERGY FUND, F.C.R.E. has reached an agreement with the partners of INTEGRAL SERVICE TO Energy infrastructure, S.L. to invest in the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-02/coinversion_wattwin.jpg" width="680" height="340" alt="Coinversión WATTWIN" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">Wattwin is a technological platform optimizes the marketing and management of projects produced solar, efficiency and electrification installer that attracts traders and engineering, which are driving energy transition in Spain. The investment of CDTI Innovation allows the company to make progress in the development of their technology and continue to grow in the sector.</p><p class="text-align-justify">Josep-Miquel Torregrosa, partner of Suma Capital, he stressed: “ since<a href="www.sumacapital.com" rel="noopener" target="_blank">Suma Capital</a>relying on technological solutions that accelerate energy transition. Wattwin is a great example of how the digitization can make more efficient energy sector and facilitate its adoption on a large scale, both residential and industrial level. The entrance to the CDTI Innovation reinforces the strength of the project and allow the company to continue to grow and improve its value proposition ".</p><p class="text-align-justify"><a href="www.sumacapital.com" rel="noopener" target="_blank">Suma Capital</a>it is an independent manager alternative assets, leader in ecological transition. Signature focuses its investments in sustainability through three different programmes: Infraestructuras Sostenibles, Capital Crecimiento and Venture Capital. Suma Capital, which manages more than eur 1 billion in assets, was founded in 2007 and has become a true european presence in Barcelona, Madrid and paris.<br /></p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 21 Feb 2025 12:15:19 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22377 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte en el fondo Impact Bridge Sustainable AgriFood Fund I Innvierte, para apoyar a las pymes agroalimentarias españolas en su crecimiento y transición hacia un modelo más sostenible</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-en-el-fondo-impact-bridge-sustainable-agrifood-fund-i</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation fund invests in Impact Bridge Sustainable AgriFood Fund I Innvierte, to support smes in their food growth and transition to a more sustainable model</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 02/25/2025 - 11:25</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-02-18T12:00:00Z" class="datetime">18 February 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation fund invests in Impact Bridge Sustainable AgriFood Fund I Innvierte, to support smes in their food growth and transition to a more sustainable model</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><ul><li class="text-align-justify">'IB Sustainable AgriFood Fund I Innvierte ’ has more than 130 million committed and is positioned as the largest private equity fund spanish aimed at investing throughout the food supply chain</li><li class="text-align-justify">The CDTI and Innovation, IEFS are investors CaixaBank anchor of the fund, which also has the support of Tikehau Capital and various industrial investors, foundations and family offices</li>
</ul></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-02/2025feb18_fei4.jpg" width="817" height="408" alt="2025feb18_FEI" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/news-0" hreflang="en">NEWS</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The CDTI Innovation through Innvierte, has committed an investment of €73.5 million in ‘ Impact Bridge Sustainable AgriFood Fund I Innvierte, RCF ’ (‘ IB SAF I ’), a private venture capital fund, launched by the management company Impact Bridge, with a target size of eur 150 million and to promote a more sustainable agri-food model in spain. With this operation, the CDTI Innovation aims to support the capitalization of innovative technology companies.</p><p class="text-align-justify">The director-general of the CDTI innovation, José Moisés Martín, said that “ to CDTI innovation is very important to support the entire ecosystem of specialised investment in technologies, where the social and environmental impact is essential. Take the opportunity to accompany this fund, which addresses a sector that has historically enjoyed few specialized investors, and where a modernization of technology-based and sustainability chart a way forward, it seems to us an opportunity to demonstrate additionality in tensile strength of private commitments that may have our presence as investor anchor, having allowed managers to tackle the process of funds. ”</p><p class="text-align-justify">IB SAF I is the largest private venture capital fund in the food industry, invests in smes to fuel growth, improve their competitiveness and create a social and environmental impact positive. Its strategic goals are supporting the rural world, the inclusion of vulnerable groups, adaptation to climate change and the preservation of biodiversity (50 per cent of the commission variable of the fund is subject to implement the objectives of impact).</p><p class="text-align-justify">This fund is supported, as well as by the CDTI Innovation, for others who share the aims to promote and implement sustainable best practices and technologically advanced in the agri-food industry.</p><p class="text-align-justify">The european investment fund (EIF) contributes with 30 million euros, to support the development of sustainable agriculture systems. CaixaBank, for its part, invests €10 million, in order to enhance their commitment to sustainability, innovation in the sector. Tikehau Capital committed eur 5 million, to promote regenerative agriculture practices. The fund also has the support of relevant institutions for the sector as the foundation Daniel and Nina Carasso and family groups specializing in agri-industry as Blanca Hernández, Dadelos e Iberhanse, among others.</p><p class="text-align-justify">IB SAF I will invest in 10-12 spanish companies located in the entire value chain and agro-industries, with an adjacent EBITDA from $1 million to $5 million euros. It will offer flexible capital solutions tailored to their specific needs in order to help them to grow and become leaders in platforms in their respective areas.<br /></p><h4 class="text-align-justify"><strong>Impact Bridge Asset Management</strong></h4><p class="text-align-justify"><a href="https://www.impactbridge.com/" rel="noopener" target="_blank">Impact Bridge</a>management is a collective investment institutions with more than eur 300 million under management specialized in impact investment of quality and focused on projects that generate a genuine impact intended and measurable. Founded in 2018, investor base consists of institutional investors, as private pension funds, foundations and family offices and public institutions, such as the european investment fund, CDTI, COFIDES and Axis (ICO).<br /></p><h4 class="text-align-justify"><strong>European investment fund (EIF)</strong></h4><p class="text-align-justify">The Eif is part of the european investment Bank. Its primary mission is to support and micro and small and medium-sized enterprises by facilitating their access to funding. The Eif designs and develops tools for risk capital and growth pact, guarantees and microfinance facilities specifically designed for purposes of this market segment. With its activity, contributed to the achievement of key objectives of eu policy, competitiveness and growth, innovation and digitalisation, the social impact, capacities and human capital, the climate and environmental sustainability.<br /></p><h4 class="text-align-justify"><strong>CaixaBank</strong></h4><p class="text-align-justify"><a href="https://www.caixabank.es/" rel="noopener" target="_blank">CaixaBank</a>it is an entity that has just launched its new triennial Sustainability, which is part of the new strategic Plan 2025-2027, which will mobilise eur 100 billion in sustainable finance for further progress towards a more sustainable economy and to promote the economic and social development of persons, with the financing of renewable energy projects, mobility clean and efficient buildings, facilitating solutions to accelerate the transition sustainable enterprises and families, promoting financial inclusion, promoting training and employment and to respond to the needs arising from rising longevity.<br /></p><h4 class="text-align-justify"><strong>Tikehau Capital</strong></h4><p class="text-align-justify"><a href="https://www.tikehaucapital.com/" rel="noopener" target="_blank">Tikehau Capital</a>it is a global asset manager alternative 47.100 million euros of assets under management (30 september 2024). Has developed a wide experience in four asset classes (credit, real assets, private equity and strategies of capital markets), as well as multiactivos strategies and special opportunities. Tikehau Capital offers solutions of financing alternatives, and as innovative enterprises invests and seeks to create long-term value their investors, at the same time as a positive impact on society.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the agency of the ministry of science, innovation and universities that supports innovation based on knowledge, advice and providing public funding for innovation through subsidies or aid partly refundable for innovation and managing public procurement, pre-commercial.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/innvierte-economia-sostenible-sicc-sme-sa" rel="noopener" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in 160 companies.</p><p class="text-align-justify">The CDTI Innovation also facilitates the internationalization of business projects of r & D and innovation of spanish companies and entities and manages the participation of spanish companies in international r & D, Horizonte Europa and Eureka, and in industries of science and space.</p><p class="text-align-justify">The centre for technological development and innovation, E.P.E. (CDTI) is a public entity under the ministry of Science, innovation and universities.</p><h4 class="text-align-justify"><strong>More information:</strong></h4><p class="text-align-justify">Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p class="text-align-justify">On The Internet<br />Website:<a href="www.cdti.es" rel="noopener" target="_blank">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" rel="noopener" target="_blank">https :// www.youtube.com/user/CDTIoficial</a></p><p class="text-align-justify">This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 18 Feb 2025 13:22:37 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22348 at http://www.cdti.es</guid>
</item>
<item>
<title>Innvierte destina en enero más de 1 millón de euros a dos nuevas coinversiones en capital riesgo</title>
<link>http://www.cdti.es/noticias/innvierte-destina-en-enero-mas-de-1-millon-de-euros-dos-nuevas-coinversiones-en-capital</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>In january Innvierte allocates more than €1 million to two new coinversiones in risk capital</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 02/05/2025 - 08:49</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-02-04T12:00:00Z" class="datetime">04 February 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>In january Innvierte allocates more than €1 million to two new coinversiones in risk capital</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">These operations, undertaken in technology-based enterprises or innovative, are aimed at the development of two platforms, one to automate and convert the market research a source of competitive advantage for businesses and another to digitize sales photovoltaic project</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-02/innvierte-mensual-ene25.jpg" width="1024" height="512" alt="Operaciones cerradas de Innvierte en enero de 2025" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/news-0" hreflang="en">NEWS</a></div>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-adjunto-nota-de-prensa">
<div class="field field--name-field-adjunto-nota-de-prensa field--type-entity-reference field--label-hidden field__item"><div>
<span class="link">
<a href="http://www.cdti.es/sites/default/files/2025-02/nota_de_prensa_20250204_cdti-innvierte_cierres_enero_1.pdf" target="_blank"><span class="icon-download"></span> Descargar documento adjunto </a></span>
</div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p>The CDTI Innovation, sponsor and sole shareholder of society Innvierte, has closed, last january, 2 joint investment operations, amounting to €1.134.000, in particular:</p><ul><li><strong>ZINKLAR (MOVIL ACCESS, S.L.)</strong>develops a platform that automates and makes market research on a daily "” and a source of competitive advantage for businesses, to enable them to do much more research with the same investment and in less time. The follow-up investment is done with CRITERIA VENTURE TECH SICC, S.A. and FULL GLOBAL INVESTMENTS S.C.R. S.A. and the commitment of the CDTI Innovation is than 594,000 euros.</li><li><strong>INTEGRATED SERVICE TO ENERGY INFRASTRUCTURE, S.L.</strong>develops a platform, WATTWIN, which digitizes the sales of photovoltaic project investment is done with ENION I ENERGY FUND, F.C.R.E. and ENION I ENERGY, F.C.R.E., S.A. and the commitment of the CDTI Innovation is of 540,000 euros.</li>
</ul><p>Since january 2025 the CDTI Innovation through Innvierte has closed operations, joint investment in 2 companies with a commitment 1.13 million euros.</p><h4> </h4><h4><strong>Innvierte</strong></h4><p>Innvierte is an initiative aimed at promoting the entrepreneurial innovation through support to the risk capital investment in technology-based enterprises or innovative programme. This is done through the collective investment type closed Innvierte Sustainable Economy SICC S.M.E., S.A., self-managed and under the supervision of the national Values and that the CDTI Innovation is a shareholder Only.</p><p>To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 160 €522M in enterprises.</p><p>Innvierte framed Estrategia española de Ciencia, tecnología e innovación 2021-2027, adopted by decision of the council of ministers, in september 2020. This Estrategia contains goals, the reforms and measures to be taken throughout the area of r + D + i in order to boost their growth and impact, and is one of the pillars on which the design of the government's policy in r + D + i for the coming years.</p><h4 class="text-align-justify"> </h4><h4 class="text-align-justify"><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology. The CDTI also supports the creation and consolidation of technology-based enterprises in Spain.</p><h4 class="text-align-justify"><br /><strong>More information:</strong></h4><p class="text-align-justify">Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p class="text-align-justify">On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" previewlistener="true" tabindex="-1">www.cdti.es</a><br />In LinkedIn:<a href="https://www.linkedin.com/company/29815" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On YouTube:<a href="https://www.youtube.com/user/CDTIoficial" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https :// www.youtube.com/user/CDTIoficial</a></p><p class="text-align-justify">This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 04 Feb 2025 09:19:42 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22258 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, FCR y SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, en QUIBIM, S.L., empresa de tecnología biomédica</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-sabadell-asabys-health-innovation-investments-ii-fcr</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., company biomedical technology</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/29/2025 - 14:05</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-29T12:00:00Z" class="datetime">29 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI Innovation invests, together with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., company biomedical technology</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, RCF and SABADELL ASABYS HEALTH INNOVATION INVESTMENTS 2B, SCR SA, QUIBIM, S.L., has reached an agreement to enter the capital of the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_quibim.jpg" width="1024" height="512" alt="Coinvrersión QUIBIM" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify"><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>leading company in health technology and pioneer in the transformation of medicine as precision machining using biomarkers of image, announced the closure of its funding round Number for a total of 50 million. The round was led by<a href="www.asabys.com" title="Asabys partners">Asabys</a>through its merits Sabadell Asabys II, and Buenavista Equity Partners, through the BHG I, created in partnership with Columbus Venture Partners, with the participation of new investors as UI Investissements and GoHub Ventures, in addition to current investors in Amadeus Capital Partners, APEX Ventures, Partech, Adara Ventures, Leadwind (KFund fund) and Build Collective, Tony Fadell. Between prominent individual investors is dr. Jonathan Milner, founder of Abcam plc —<br /><br /><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>works with the ambitious aim to understand what is happening in each of the tissues of the human body, at any time and a noninvasive. To achieve this, the company develops models of IA applied to medical image to extract useful information from mri (RM), assessed (TC) and ct emission positrons (PET). These developments can characterize the phenotype results and to predict accurately in Clinical oncology, as the immunology, neuroscience and study of metabolic disorders.</p><p class="text-align-justify"><img alt="QR PROSTATE" data-entity-type="file" data-entity-uuid="8de4e3c9-20ef-4361-8a77-c3eab58962b0" src="http://www.cdti.es/sites/default/files/inline-images/qp-prostate_2.png" width="1920" height="1011" loading="lazy" /></p><p class="text-align-justify">A viewer prostate RM einforme structured to atlas of the prostate, with the presence of an injury.</p><p class="text-align-justify">With the financing of the Series A,<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>consolidates a strong presence in united states, following its success in europe, through strategic partnerships with hospitals and pharmaceutical companies. In line with its strategic plan and building on its range of solutions authorized by the FDA, the company will support to hospitals and clinical researchers in the efficient processing of large volumes of data from medical imaging. In Addition, the image solutions IA driven<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>will allow pharmaceutical companies to significantly improve the effectiveness of their clinical trials and accelerate the development of drugs, providing useful and accurate information derived from biomarkers of image.</p><p> </p><h4><strong>QUIBIM</strong></h4><p class="text-align-justify"><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>it is a health technology company pioneer in the development of tools that extract and processed information hides in medical imaging for improving clinical outcomes for patients.<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>it is at the forefront of research of biomarkers of image in life sciences, encouraging the development of advanced algorithms that convert the image data indictable predictions in oncology, immunology and neurology. The company uses the capabilities of the magnetic resonance imaging (MRI), computerized tomography (CT) and emission positrons (PET) to create medical devices, integrated perfectly into the flows of care providers around the world.</p><p class="text-align-justify">More than 170 health institutions, research centres, hospitals and clinics Quibim use throughout the world. In addition,<a href="https://quibim.com/" title="Web de Quibim">Quibim</a>collaborates with Merck KGaA in the development of models of biomarkers of image you predict the response of oncological patients to allergies and inspiring decisions in their overall efforts of new drugs, as well as with Philips in the launching of image solutions and generates reports based on IA for prostate cancer.<br /><a href="https://quibim.com/" title="Web de Quibim">Quibim</a>has offices in new York (USA), Cambridge (Uk), Valencia, Madrid and Barcelona (España).</p><p> </p><h4><strong>ASABYS PARTNERS</strong></h4><p class="text-align-justify"><a href="www.asabys.com" title="Asabys partners">Asabys Partners</a>it is a venture capital firm specialized in the health sector, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, and with the support of Banc Sabadell as anchor. Asabys investor invests in innovative companies and disruptive covering medical needs not covered in the vertical biofarma and health. Investment in the company comes from their vehicles Sabadell Asabys Health Innovation Investments II, RCF and Sabadell Asabys Health Innovation Investments 2B, SCR SA.</p><p> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Wed, 29 Jan 2025 11:39:30 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22233 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-en-la-empresa-estrategica-oncomatryx-biopharma-sl-pionera-en</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 01/28/2025 - 16:31</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-28T12:00:00Z" class="datetime">28 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte en la empresa estratégica ONCOMATRYX BIOPHARMA S.L., pionera en el desarrollo de fármacos contra el microambiente tumoral</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p>The CDTI Innovation through the co-investment in strategic enterprises of its agenda Innvierte, has reached an agreement with the partners of ONCOMATRYX BIOPHARMA S.L. to enter the capital of the company</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_oncomatryx_biopharma.jpg" width="680" height="340" alt="Coinversión ONCOMATRYX BIOPHARMA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The pioneering work<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>focuses on the development of customized biofarmacéuticos medicines against tumor microambiente, to address invasive stages of cancer, which still have a high mortality rate.</p><p class="text-align-justify">After 14 years of research, the company<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx Biopharma</a>has received some promising results in the clinical trial phase I of its latest generation drug OMTX 705. OMTX 705 is a conjugated antibody (ADC) directed against the microambiente surrounding the tumor and favour their immunosuppression, invasion and metastasis. The results of the clinical trial have confirmed the efficacy and safety of OMTX705, as demonstrated in animal models.</p><p class="text-align-justify"><a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>located in the Parque tecnológico de Bizkaia, has identified new mechanisms and protein peritumoral estroma, cells and extracellular matrix that surround the tumor and facilitate their invasividad, immunosuppression, resistance to treatment and metastasis.</p><p class="text-align-justify"><a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>has addressed the development of these pioneers drugs mechanisms and protein peritumoral estroma, in collaboration with leading universities, hospitals and research centres in the usa and europe, such as Harvard university, MD Anderson Cancer Center, university of Stuttgart, university of turin, university of bologna, CIC-Biogune, research centre of Salamanca, national research Centre Of Oncological, Onkologikoa, Hospital Virgen del Rocío, Hospital Sant Joan de Deu Hospital Universitario de Valdecilla, Hospital 12 october, Catalan Institute of oncology and University Clinic of navarre.</p><p class="text-align-justify">It is noteworthy that the funds of the capital increase, along with recurrent income<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>from these licence agreements with large international biofarmacéuticas, will provide new cohorts of expansion in clinical trials, which will allow for a best characterization of proven effectiveness. Furthermore, it will be allocated to the clinical development of new drugs (antibodies because) of the pipeline of<a href="www.oncomatryx.com" title="Web de Oncomatryx">Oncomatryx</a>against microambiente microenvironment.</p><h4> </h4><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 28 Jan 2025 11:46:31 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22228 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</title>
<link>http://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-inveready-biotech-iv-scr-sa-inveready-biotech-iv</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/29/2025 - 11:31</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-24T12:00:00Z" class="datetime">24 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>El CDTI Innovación invierte, junto con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A., en GENIOVA TECHNOLOGIES S.L</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">El CDTI Innovación, a través de su programa Innvierte, conjuntamente con INVEREADY BIOTECH IV S.C.R, S.A, INVEREADY BIOTECH IV PARELLEL S.C.R., S.A, e INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I S.C.R, S.A. ha alcanzado un acuerdo con los socios de GENIOVA TECHNOLOGIES S.L, para invertir en la compañía</p></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_geniova.jpg" width="817" height="408" alt="Coinversión GENIOVA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The company<a href="https://geniova.com/" rel="noopener" target="_blank">Geniova Technologies S.L.</a>, in the area of wholesale trade of dental products, has developed a new technology of aligners with a new product, accelerating the movement of the teeth, to accelerate the process of alignment.</p><p class="text-align-justify">The commitment by Geniova CDTI, accompanied by the participation of current shareholders of the company, emphasizes the reliance on the potential of the hybrid technical Geniova. An invisible braces which combines the advantages of the modern aligners and the brackets, reaching 94 per cent of predictability. With FDA approved in United states and by investing Geniova received, will strengthen its presence in Europe, america and Asia, while promoting initiatives of R & D and sustainable production. The support of the CDTI Innvierte reinforces the long-term strategy of the company and the mutual commitment to promote health technologies with a positive impact in society.</p><h4 class="text-align-justify"><br /><strong>GENIOVA TECHNOLOGIES</strong></h4><p class="text-align-justify">Geniova is pioneer in orthodontics invisible, with more than 10 years of research and development devoted to refine its patented hybrid technique. This innovative system combines comfort with a removable aligners lingual arc nickel and titanium (NiTi), capable to match the speed of the fixed braces. Since its inception, has revolutionized Geniova invisible braces, providing effective treatment, invisible and secure environment capable of reaching a rate of predictability of 94 per cent. In Addition, it integrates greening initiatives and manufacturing practices responsible in each stage of its production, strengthening their global positioning and commitment to sustainability, innovation and excellence in orthodontics.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>INVEREADY</strong></h4><p class="text-align-justify"><a href="https://inveready.com/" rel="noopener" target="_blank">Inveready</a>it is an alternative asset manager leader in southern europe with more than eur 2 billion in assets under management and a strong focus on technological companies of high growth. With more than 15 years of trajectory reified sales and 64, provides financing solutions to companies throughout the life cycle, since the initial phase to the most advanced.<br /></p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" tabindex="-1" target="_blank">CDTI Innovation</a>it is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative<a href="https://www.cdti.es/programa-innvierte" rel="noopener" tabindex="-1" target="_blank">Innvierte Economía Sostenible</a>, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es" tabindex="-1">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" tabindex="-1" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial" tabindex="-1">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" tabindex="-1" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 24 Jan 2025 11:39:32 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22220 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI invierte, junto con NARA CAPITAL, en Tesai Care SL, empresa de dispositivos médicos para prevenir y tratar la atrofia muscular respiratoria con electroestimulación no invasiva</title>
<link>http://www.cdti.es/noticias/el-cdti-invierte-junto-con-nara-capital-en-tesai-care-sl-empresa-de-dispositivos-medicos</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests, together with NARA CAPITAL, in Tesai Care SL, medical devices to prevent and treat respiratory muscle atrophy electrostimulation with non-invasive</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/15/2025 - 07:40</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-10T12:00:00Z" class="datetime">10 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests, together with NARA CAPITAL, in Tesai Care SL, medical devices to prevent and treat respiratory muscle atrophy electrostimulation with non-invasive</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation invests, together with NARA HEALTH CAPITAL I, F.C.R., TESAI CARE S.L., a start-up of medical technology that develops heecap ®, medical device of the non-invasive electrostimulation and custom designed to prevent and treat the atrophy respiratory muscle (diaphragm and abdominal) in patients who are in Intensive care units (UCI) supports Mechanical Ventilation and works in a synchronized with the patient</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_tesai_care.jpg" width="836" height="418" alt="Coinversión TESA CARE" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The<a href="https://www.cdti.es/" rel="noopener" target="_blank">CDTI Innovation</a>through its programme, together with Innvierte<a href="https://www.nara.capital/" rel="noopener" target="_blank">NARA HEALTH CAPITAL I, F.C.R.</a>, has reached an agreement with the partners of TESAI CARE, S.L., to enter the capital of the company.</p><p class="text-align-justify"><a href="www.heecap.com" rel="noopener" target="_blank">Tesai Care S.L.</a>it is a spanish medtech spin-off Parc Taulí Hospital and Hospital Vall d ’ Hebron that is developing heecap ® a device that provides a Unique treatment strategy in the area of health, based on the non-invasive electrical stimulation to maintain the strength of respiratory muscle in patients who need support mechanical ventilation (VM).</p><p class="text-align-justify">The VM is a technique that saves lives in critical patients, but presents a major challenge: 76 per cent of patients ventilated develop respiratory muscle atrophy because prolonged disused diaphragm and other respiratory muscles, a problem that affects more than 3 million people per year throughout the world. This weakness makes the disconnection of ventilation, which prolonged stays in the UCI and delay recovery.</p><p class="text-align-justify">The device heecap ® uses estimulación eléctrica transcutánea de los músculos Respiratorios (TERM, by its initials in english), sincronizándose with the patient to strengthen the muscles inspiratorios and espiratorios. With this technique, is to upgrade the muscular strength and facilitate the process of disengagement from the mechanical ventilation.</p><p class="text-align-justify">The device consisting of three main components: electrodes being placed on the patient and adapt in a personalized way, a device of electrical stimulation, and an algorithm that synchronizes the stimulation with respiratory cycles.</p><p class="text-align-justify">Tesai Care launched last october a clinical trial with the device heecap ®, after the approval of the spanish agency of medicines and Productos Sanitarios (AEMPS), for the purpose of confirming the safety and integrity of the system, as well as to confirm that the algorithm operates with precision.</p><p class="text-align-justify"> </p><p class="text-align-justify"><img alt="Heecap device" data-entity-type="file" data-entity-uuid="3d56db58-fb6b-4101-b494-8f316f373836" src="http://www.cdti.es/sites/default/files/inline-images/dispositivo_heecap_utilizado_por_enfermera_en_hospital_parc_tauli.jpeg" width="1440" height="1080" loading="lazy" /></p><p class="text-align-justify">Heecap device being used by a nurse in Hospital Parc Taulí<br /></p><p class="text-align-justify">The funds contributed by CDTI INNVIERTE and NARA CAPITAL combined with public and private financing, the company will enable progress in clinical studies needed for the market heecap ®, with the purpose of seeking the CE marking as a health product in 2026.</p><p class="text-align-justify">heecap ® has the potential to significantly improve the quality of life of patients critics, accelerating their autonomy, reducing the days of mechanical ventilation and income in the UCI, and reducing potential complications to income, such as infections. According to the canadian medical recognized intensivista Ewan Goligher, “ technical approximation heecap has the potential to become a new standard of treatment for patients ventilated ”.<br /></p><h4 class="text-align-justify"><strong>NARA HEALTH CAPITAL I, F.C.R.</strong></h4><p class="text-align-justify">Nara Capital management is a private capital invested in Biopharma businesses and HealthTech from technology transfer of research centres. Nara invests in projects and disruptive transformers in their initial stages of research and development.</p><p class="text-align-justify">Nara takes its in-depth knowledge of the sector to incorporate capital and operational capacities to startups, with the dual aim to generate long-term value their investors and create a positive impact on health and quality of life of patients and of society.</p><p class="text-align-justify"> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Fri, 10 Jan 2025 12:42:56 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22153 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI invierte junto con Ysios Capital y Asabys Partners en Anaconda Biomed, empresa de dispositivos médicos neurovasculares</title>
<link>http://www.cdti.es/noticias/el-cdti-invierte-junto-con-ysios-capital-y-asabys-partners-en-anaconda-biomed-empresa-de</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests together with Ysios Capital and Asabys Partners in Anaconda Biomed, medical devices company neurovasculares</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 01/15/2025 - 12:27</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2025-01-09T12:00:00Z" class="datetime">09 January 2025</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI invests together with Ysios Capital and Asabys Partners in Anaconda Biomed, medical devices company neurovasculares</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">The CDTI Innovation invests, together with YSIOS BIOFUND II INNVIERTE F.C.R, YSIOS BIOFUND II SIDE FUND F.C.R.E., SABADELL ASABYS HEALTH INNOVATION INVESTMENTS II, F.C.R. and ASABYS TOP UP FUND F.C.R., ANACONDA BIOMED S.L, company dedicated to the design, development and manufacture of medical devices neurovasculares. Its innovative product is the ANA Funnel Catheter, an advanced system designed to maximize the efficacy and safety of the mechanical trombectomías in the treatment of acute ischaemic stroke</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2025-01/coinversion_anaconda_09012025.jpg" width="836" height="418" alt="Coinversión ANACONDA" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">The CDTI Innovation, through its programme, together with Innvierte Ysios Capital and Asabys Partners, has reached an agreement with Anaconda Biomed to invest in the company.</p><p class="text-align-justify">Anaconda Biomed, based in spain, is in advanced stages clinics with your device ANA Funnel Catheter, a pioneering system designed to improve both efficiency as the safety of mechanical trombectomías in the treatment of acute ischaemic stroke, a major cause of death and disability in the world.</p><p class="text-align-justify">With a social and economic impact significantly, the stroke represents a critical challenge to the global level. According to recent data the stroke will affect the 25 per cent of adults aged 25 plus throughout their lives and represents an annual cost of more than eur 60 billion in europe. The innovation of Anaconda Biomed aligns itself with the public health goals, providing tools to address this issue.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>ANA Funnel Catheter</strong></h4><p class="text-align-justify">ANA5 Advanced Neurovascular Access ™ (ANA Funnel Catheter) is a catheter designed to help neurovasculares procedures. The device consisting of a mesh of nitinol radiopaco in a sweep topped with a layer polimérica that allows for the arrest local flow. Currently, this catheter is a device under investigation and is not available for sale in the united states or in the european union.</p><h4 class="text-align-justify"><br /><strong>Anaconda Biomed</strong></h4><p class="text-align-justify">Anaconda Biomed is an innovative company medical technology solutions to the latest generation trombectomía for the treatment of ischaemic stroke in the heart of its portfolio of products is ANA Funnel Catheter.</p><p class="text-align-justify">Anaconda Biomed has received funding of leading firms in life sciences, as Ysios Capital, Omega Funds, Innogest, Asabys Partners, Banco Sabadell and private investors. Moreover, through public subsidies, the company has been supported by INNVIERTE, INICIATIVA DE INVERSIÓN DE CDTI, E.P.E, Enisa, CDTI (Neotec), the ministry of science and innovation (programmes and Emplea Retos), the EIB EIT and Health.</p><p class="text-align-justify"> </p><h4 class="text-align-justify"><strong>Ysios Capital Partners</strong></h4><p class="text-align-justify">Ysios Capital is a spanish leading manager in venture capital which provides funding to enterprises of life sciences highly innovative treatments that are aimed at indications with a large medical need not covered. With offices in San Sebastian and Barcelona, is formed by a team of professionals diverse which aims to transform the capital in medical breakthroughs with a positive impact on society. Ysios Capital, founded in 2008, has more than eur 400 million in assets under management through its three funds.</p><h4 class="text-align-justify"><br /><strong>Asabys Partners</strong></h4><p class="text-align-justify">Asabys Partners is a specialized risk capital in health, founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs Alantra owned, with the support of the Banco Sabadell anchor. investor With around €300 million in assets under management and 18 owned Asabys invests in innovative companies disruptive and addressing unmet medical needs in the areas of biotechnology and pharmaceuticals and health technology investment in this company has been made since their vehicles Sabadell Asabys Health Innovation Investments SCR, SA, and Asabys Top Up Fund, RCF.</p><p class="text-align-justify"> </p><h4><strong>CDTI Innovation</strong></h4><p class="text-align-justify">The CDTI innovation is the public funding of innovation of the ministry of science, innovation and universities that promotes innovation and technological development of spanish companies, channeling requests for funding and support for r & D & I projects of spanish entities at the state and international levels. We Contribute to the improvement of the technological level of spanish companies and drive and, with an international network with coverage of 51 countries support the spanish participation in international programmes for technology cooperation and the international transfer of technology.</p><p class="text-align-justify">Additionally, through the initiative Innvierte Sustainable Economy, supports and facilitates the capitalization of technology companies. To date, the CDTI Innovation, through Innvierte, committed 1,795 M €in 42 investment vehicles that have invested in more than 271 companies, and through its joint investment line directly committed an amount of more than 522 M €in at least 160 companies.</p><p class="text-align-justify"> </p><h4><strong>More information:</strong></h4><p>Office of the press<br /><a href="mailto:prensa@cdti.es" rel="noopener" target="_blank">prensa@cdti.es</a><br />91-581.55.00</p><p>On The Internet<br />Website:<a href="https://www.cdti.es/noticias/www.cdti.es">www.cdti.es</a><br />In Linkedin:<a href="https://www.linkedin.com/company/29815" rel="noopener" target="_blank">https :// www.linkedin.com/company/29815</a><br />X:<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">https :// twitter.com/CDTI _ innovation</a><br />On Youtube:<a href="https://www.youtube.com/user/CDTIoficial">https :// www.youtube.com/user/CDTIoficial</a></p><p>This content is copyright © 2025 CDTI, Soes. Permitted for use and reproduction by quoting the source and digital identity of CDTI (<a href="https://twitter.com/CDTI_innovacion" rel="noopener" target="_blank">@CDTI _ innovation</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Thu, 09 Jan 2025 15:16:34 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22150 at http://www.cdti.es</guid>
</item>
<item>
<title>Innvierte destina en octubre y noviembre más de 350 millones de euros a ocho nuevas coinversiones en capital riesgo y cinco vehículos de inversión</title>
<link>http://www.cdti.es/noticias/innvierte-destina-en-octubre-y-noviembre-mas-de-350-millones-de-euros-ocho-nuevas</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>Innvierte allocates more than 350 million euros in October and November to eight new co-investments in venture capital and five investment vehicles.</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Wed, 12/11/2024 - 14:31</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-12-09T12:00:00Z" class="datetime">09 December 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>Innvierte allocates more than 350 million euros in October and November to eight new co-investments in venture capital and five investment vehicles.</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><p class="text-align-justify">Desde enero de 2024 el CDTI Innovación, a través de Innvierte, ha cerrado operaciones de coinversión en 52 empresas con un compromiso de 85,1 millones de euros, e inversiones en 10 vehículos de inversión con un compromiso de 628 millones de euros</p>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-12/innvierte-mensual-octynov24.jpg" width="1024" height="512" alt="Cierres octubre y noviembre 2024 Innvierte" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/news-0" hreflang="en">NEWS</a></div>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-adjunto-nota-de-prensa">
<div class="field field--name-field-adjunto-nota-de-prensa field--type-entity-reference field--label-hidden field__item"><div>
<span class="link">
<a href="http://www.cdti.es/sites/default/files/2024-12/nota_de_prensa_20241209_cdti-innvierte_cierres_octubre_y_noviembre.pdf" target="_blank"><span class="icon-download"></span> Descargar documento adjunto </a></span>
</div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">El CDTI Innovación, promotor y accionista único de la sociedad Innvierte, ha cerrado, en los pasados meses de octubre y noviembre, 8 operaciones de coinversión, por importe de 18.111.000 euros, en concreto: <br />
</p>
<ul><li class="text-align-justify"><strong>EZZING RENEWABLE ENERGIES, S.L.</strong> ha creado una plataforma online para gestionar toda la cadena de valor de la generación de energía fotovoltaica, que incluye un conjunto de funcionalidades que permiten obtener un diseño eficiente a nivel técnico y de rendimiento de este tipo de instalaciones. La inversión de seguimiento se realiza con REPSOL ENERGY VENTURES, S.A. y la aportación del CDTI Innovación es de 180.000 euros</li>
<li class="text-align-justify"><strong>INBRAIN NEUROELECTRONICS, S.L.</strong> desarrolla terapias bioelectrónicas que emplean implantes de interfaces de grafeno que decodifican y modulan la actividad neuronal en alta resolución, dando origen a terapias adaptativas y personalizadas. La inversión de seguimiento se realiza con Sabadell Asabys Health Innovation Investments, SCR, SA, Asabys Top Up Fund FCR y ALTA Life Sciences Spain I FCR y la aportación del CDTI Innovación es de 4.050.000 euros.</li>
<li class="text-align-justify"><strong><a href="https://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-inveready-first-capital-iii-parallel-fcr-e-inveready" rel="noopener" target="_blank">LINKING REALITIES, S.L. (UNION AVATARS) </a></strong>ha desarrollado una plataforma de creación de avatares para que sus clientes puedan ofrecer una representación de sus usuarios, ya sea en videojuegos, redes sociales, mundos de realidad virtual o gamificación difuminando las líneas entre el mundo virtual y la realidad, a través de tecnología 3D que acerca los mundos virtuales y ayudar a dar forma al futuro de la identidad virtual. La inversión se realiza junto con INVEREADY FIRST CAPITAL III PARALLEL, F.C.R. e INVEREADY FIRST CAPITAL III S.C.R.E., S.A. y la aportación del CDTI Innovación es de 328.000 euros.</li>
<li class="text-align-justify"><strong><a href="https://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-gpc-en-tebrio-empresa-biotecnologica-del-sector-de" rel="noopener" target="_blank">TEBRIO (MEALFOOD EUROPE, S.L.)</a></strong> se dedica a la cría industrial y transformación del insecto Tenebrio Molitor (gusano de la harina). Los productos que obtiene son proteínas y grasas para consumo animal, fertilizante ecológico y quitosano. La inversión de seguimiento se realiza con GARCÍA PÉREZ CONSULTING, S.L. y el compromiso del CDTI Innovación es de 6.931.000 euros.</li>
<li class="text-align-justify"><strong><a href="https://www.cdti.es/noticias/el-cdti-innovacion-invierte-junto-con-geroa-pentsioak-epsv-y-ampo-scoop-en-bidasoa-metal" rel="noopener" target="_blank">BIDASOA METAL 78, S.L.</a></strong> desarrolla una tecnología hidrometalúrgica, para la recuperación de metales preciosos del grupo del platino (PGMs), que permite su recuperación a partir de catalizadores de vehículos de motor, con una reducción del 65% de las emisiones de CO2. La inversión se realiza con GEROA PENTSIOAK EPSV DE EMPLEO PREFERENTE, y AMPO, S.COOP. y el compromiso del CDTI Innovación es de 252.000 euros.</li>
<li class="text-align-justify"><strong>CORIFY CARE, S.L. </strong>desarrolla un dispositivo médico que permite determinar con precisión el origen de arritmias cardíacas de una forma sencilla, segura y no invasiva. La inversión de seguimiento se realiza con Mondragón Fondo de Promoción FCR y la aportación del CDTI Innovación es de 630.000 euros.</li>
<li class="text-align-justify"><strong>CRISALION MOBILITY, S.L.</strong> (antes UMILES NEXT, S.L.) desarrolla soluciones de movilidad -aéreas y terrestres- avanzadas, eficientes y sostenibles. La inversión de seguimiento se realiza con FUNDACIÓN TECNALIA RESEARCH & INNOVATION y CUYAM S.L. y la aportación del CDTI Innovación es de 5.341.000 euros.</li>
<li class="text-align-justify"><strong>PANGEA AEROSPACE, S.L.</strong> desarrolla sistemas de propulsión espacial. La inversión de seguimiento se realiza con PRIMO SPACE y la aportación del CDTI Innovación es de 399.000 euros.</li>
</ul><h4 class="text-align-justify"><br /><strong>Vehículos de inversión:</strong></h4>
<p class="text-align-justify">Durante los pasados meses de octubre y noviembre, el CDTI Innovación, por medio de Innvierte, ha comprometido inversiones en 5 vehículos de inversión por importe de 333 millones de euros. En concreto:</p>
<ul><li class="text-align-justify"><strong>ARTÁ CAPITAL FUND III, FCR,</strong> gestionado por ARTÁ CAPITAL, SGEIC, S.A., invertirá en compañías de diversos sectores que cuenten con un perfil de liderazgo en sus sectores y con cierto nivel de consolidación y rentabilidad probada. El compromiso del CDTI Innovación es de 60 millones de euros.</li>
<li class="text-align-justify"><strong>BV HEALTHCARE GROWTH I INNVIERTE, FCR,</strong> gestionado por GED IBERIAN PRIVATE EQUITY S.A.U. SGEIC, invertirá en compañías de diversos segmentos del sector salud en fase de producción y/o comercialización, con visión de expansión internacional. El compromiso del CDTI Innovación es de 58,8 millones de euros.</li>
<li class="text-align-justify"><strong>INVEREADY INNVIERTE CONVERTIBLE TECH NOTES I, S.C.R., S.A.</strong> gestionado por INVEREADY ASSET MANAGEMENT, S.G.E.I.C, S.A. invertirá principalmente a través de préstamos convertibles en compañías de los sectores de ciencias de la vida, telemedicina, telecomunicaciones, ciberseguridad, software empresarial, e-commerce, social media, B2B SaaS, móvil, Big Data, IA y otros segmentos de alto crecimiento y con base tecnológica o innovadora diferencial. El compromiso del CDTI Innovación es de 24,5 millones de euros.</li>
<li class="text-align-justify"><strong>INVEREADY INNVIERTE PRIVATE EQUITY II, S.C.R., S.A.</strong> gestionado por INVEREADY ASSET MANAGEMENT, S.G.E.I.C, S.A. invertirá en compañías en fase de crecimiento y con capacidad de expansión, incluyendo los sectores de salud, tecnología, biotecnología, infraestructuras, industrial, la energía, y telecomunicaciones. El compromiso del CDTI Innovación es de 149,7 millones de euros.</li>
<li class="text-align-justify"><strong>STELLUM GROWTH I, S.C.R., S.A.</strong> gestionado por STELLUM GESTORA DE ACTIVOS SGEIC, S.A. invertirá en empresas con capacidad de expansión pertenecientes, principalmente y sin ser limitativo, a los sectores: tecnología, biotecnología, salud, infraestructuras, industrial, energía y/o telecomunicaciones. El compromiso del CDTI Innovación es de 40 millones de euros.</li>
</ul><p class="text-align-justify">Desde enero de 2024 el CDTI Innovación, a través de Innvierte, ha cerrado operaciones de coinversión en 52 empresas con un compromiso de 85,1 millones de euros, y ha cerrado inversiones en 10 vehículos de inversión con un compromiso de 628 millones de euros.</p>
<h4 class="text-align-justify"><strong>Innvierte</strong></h4>
<p class="text-align-justify">Innvierte es una iniciativa cuyo objetivo es promover la innovación empresarial mediante el apoyo a la inversión de capital riesgo en empresas de base tecnológica o innovadoras. Este programa se instrumenta a través de la sociedad de inversión colectiva de tipo cerrado Innvierte Economía Sostenible SICC S.M.E., S.A., auto gestionada y sometida a la supervisión de la Comisión Nacional del Mercado de Valores y de la que el CDTI Innovación es accionista único.</p>
<p class="text-align-justify">Hasta la fecha, el CDTI Innovación, por medio de Innvierte, ha comprometido 1.795 M€ en 42 vehículos de inversión que han invertido en más de 271 empresas, y a través de su línea de coinversión ha comprometido directamente un importe de más de 522M€ en 160 empresas.</p>
<p class="text-align-justify">Innvierte se enmarca en la Estrategia Española de Ciencia, Tecnología e Innovación 2021-2027, aprobada por Acuerdo del Consejo de Ministros, en septiembre de 2020. Esta Estrategia contiene los objetivos, las reformas y las medidas que deben adoptarse en todo el ámbito de la I+D+i con el fin de impulsar su crecimiento e impacto, y es uno de los pilares sobre los que se asienta el diseño de la política del Gobierno en I+D+i para los próximos años.</p>
<h4 class="text-align-justify"><strong>CDTI Innovación</strong></h4>
<p class="text-align-justify">El CDTI Innovación es la entidad pública de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades que promueve la innovación y el desarrollo tecnológico de las empresas españolas, canalizando las solicitudes de financiación y apoyo a los proyectos de I+D+I de entidades españolas en los ámbitos estatal e internacional. Contribuimos a la mejora del nivel tecnológico de las empresas españolas e impulsamos y, con una red internacional con cobertura de 51 países, acompañamos la participación española en programas internacionales de cooperación tecnológica y la transferencia internacional de su tecnología empresarial. El CDTI también apoya la creación y consolidación de empresas de base tecnológica en España.</p>
<h4 class="text-align-justify"><br /><strong>Más información:</strong></h4>
<p class="text-align-justify">Oficina de Prensa<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />
91-581.55.00</p>
<p class="text-align-justify">En Internet<br />
Sitio web: <a href="https://www.cdti.es/noticias/www.cdti.es" previewlistener="true" tabindex="-1">www.cdti.es</a><br />
En LinkedIn: <a href="https://www.linkedin.com/company/29815" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.linkedin.com/company/29815</a><br />
En X: <a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://twitter.com/CDTI_innovacion</a><br />
En YouTube: <a href="https://www.youtube.com/user/CDTIoficial" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.youtube.com/user/CDTIoficial</a></p>
<p class="text-align-justify">Este contenido es copyright © 2024 CDTI,EPE. Está permitida la utilización y reproducción citando la fuente y la identidad digital de CDTI (<a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">@CDTI_innovacion</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Mon, 09 Dec 2024 14:27:40 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22060 at http://www.cdti.es</guid>
</item>
<item>
<title>El CDTI compromete más de 1.000 millones en fondos de capital riesgo y en coinversiones a través de Innvierte</title>
<link>http://www.cdti.es/noticias/el-cdti-compromete-mas-de-1000-millones-en-fondos-de-capital-riesgo-y-en-coinversiones</link>
<description><span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI commits more than 1,000 million euros in venture capital funds and co-investments through Innvierte.</h1></span>
<span class="field field--name-uid field--type-entity-reference field--label-hidden"><span lang="" about="http://www.cdti.es/en/user/22949" typeof="schema:Person" property="schema:name" datatype="" content="comunicacionsupereditor" xml:lang="">comunicacionsu…</span></span>
<span class="field field--name-created field--type-created field--label-hidden">Tue, 12/10/2024 - 16:36</span>
<div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-fecha">
<div class="field field--name-field-fecha field--type-datetime field--label-hidden field__item"><time datetime="2024-12-03T12:00:00Z" class="datetime">03 December 2024</time></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiatitle">
<span class="field field--name-title field--type-string field--label-hidden"><h1>The CDTI commits more than 1,000 million euros in venture capital funds and co-investments through Innvierte.</h1></span>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-entradilla">
<div class="field field--name-field-entradilla field--type-text-long field--label-hidden field__item"><p></p><ul><li class="text-align-justify">El Consejo de Administración de Innvierte ha aprobado en julio, septiembre, octubre y noviembre compromisos de participación en 17 fondos de capital riesgo, con una aportación global de 1.007 millones de euros</li>
<li class="text-align-justify">Se han aprobado además 26 nuevas coinversiones en los sectores Bio, Salud y Agroalimentación (10), TIC (7), Industria (6), Energía y Medio Ambiente (2) y Otros (1) y dos coinversiones estratégicas, con un compromiso global de aportación de Innvierte de 51 millones de euros</li>
</ul></div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-imagen-principal">
<div class="field field--name-field-imagen-principal field--type-entity-reference field--label-hidden field__item"> <img loading="lazy" src="http://www.cdti.es/sites/default/files/2024-12/3dic-np_innvierte_cdas_2o_semestre_2024_0.jpg" width="1024" height="512" alt="Datos Consejos Innvierte semestre 2 2024" typeof="foaf:Image" class="img-fluid" /></div>
</div>
</div>
</div>
</div></div><div class="_none"><div class="container">
<div class="layout row layout-builder__layout">
<div class="col-lg-3 col-md-3 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiafield-categoria">
<div class="field field--name-field-categoria field--type-entity-reference field--label-hidden field__items">
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27854" hreflang="en">INNVIERTE</a></div>
<div class="field__item"><a href="http://www.cdti.es/en/taxonomy/term/27849" hreflang="en">INVESTMENT</a></div>
</div>
</div>
<div class="block block-layout-builder block-field-blocknodenoticiafield-adjunto-nota-de-prensa">
<div class="field field--name-field-adjunto-nota-de-prensa field--type-entity-reference field--label-hidden field__item"><div>
<span class="link">
<a href="http://www.cdti.es/sites/default/files/2024-12/2024_12_03_nota_de_prensa_fondoscoinversion-consejos_de_innvierte_jul-nov.pdf" target="_blank"><span class="icon-download"></span> Descargar documento adjunto </a></span>
</div>
</div>
</div>
</div>
<div class="col-lg-9 col-md-9 col-12">
<div class="block block-layout-builder block-field-blocknodenoticiabody">
<div class="clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item"><p class="text-align-justify">El CDTI Innovación, Entidad Pública Empresarial (E.P.E.) adscrita al Ministerio de Ciencia, Innovación y Universidades, ha comprometido a través de Innvierte un paquete de participación en diecisiete fondos de capital riesgo y 28 coinversiones superior a los 1.000 millones de euros, que fueron aprobados por los Consejos de Administración de Innvierte de los pasados 30 de julio, 11 de septiembre, 11 de octubre y 29 de noviembre.</p>
<p class="text-align-justify">En concreto, los compromisos de participación en diecisiete fondos de capital riesgo ascienden a una aportación global, por parte de Innvierte, de 1.006,9 millones de euros, según en siguiente desglose:<br />
</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">17 fondos de capital riesgo</th>
<th class="text-align-center" scope="col" style="width: 151px;">Compromisos de Innvierte (M€)</th>
</tr></thead><tbody><tr><td style="width: 401px;">6 Generalista</td>
<td class="text-align-center" style="width: 151px;">535,2</td>
</tr><tr><td style="width: 401px;">4 Bio, Salud y Agroalimentación </td>
<td class="text-align-center" style="width: 151px;">207,7</td>
</tr><tr><td style="width: 401px;">5 TIC</td>
<td class="text-align-center" style="width: 151px;">211,0</td>
</tr><tr><td style="width: 401px;">1 Industria</td>
<td class="text-align-center" style="width: 151px;">28,5</td>
</tr><tr><td style="width: 401px;">1 Energía y Medio Ambiente</td>
<td class="text-align-center" style="width: 151px;">24,5</td>
</tr><tr><td class="text-align-right" style="width: 401px;"><strong>Total</strong></td>
<td class="text-align-center" style="width: 151px;"><strong>1.006,9</strong></td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Con respecto a la fase de desarrollo o madurez de los fondos en los que se ha comprometido la participación (2 en Cataluña, 12 en Madrid y 3 en el País Vasco), siguiendo las definiciones acordadas entre las principales asociaciones europeas de capital riesgo, se reparten del siguiente modo:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Madurez fondo </th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de fondos</th>
</tr></thead><tbody><tr><td style="width: 401px;">Semilla</td>
<td class="text-align-center" style="width: 151px;">4</td>
</tr><tr><td style="width: 401px;">Arranque</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">Otras fases iniciales</td>
<td class="text-align-center" style="width: 151px;">5</td>
</tr><tr><td style="width: 401px;">Later stage venture</td>
<td class="text-align-center" style="width: 151px;">2</td>
</tr><tr><td style="width: 401px;">Capital desarrollo </td>
<td class="text-align-center" style="width: 151px;">5</td>
</tr></tbody></table><p> </p>
<h4 class="text-align-justify"><strong>Compromisos de coinversión </strong></h4>
<p class="text-align-justify">Conjuntamente, se han aprobado también coinversiones en 26 empresas (de las cuales 8 son empresas nuevas en Innvierte), con un compromiso de aportación de Innvierte de 38,5 millones de euros, según el siguiente desglose:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">26 empresas con 27 rondas aprobadas</th>
<th class="text-align-center" scope="col" style="width: 151px;">Compromisos de Innvierte (M€)</th>
</tr></thead><tbody><tr><td style="width: 401px;">10 empresas de Bio, Salud y Agroalimentación</td>
<td class="text-align-center" style="width: 151px;">16,9</td>
</tr><tr><td style="width: 401px;">7 empresas del sector TIC</td>
<td class="text-align-center" style="width: 151px;">2,8</td>
</tr><tr><td style="width: 401px;">6 empresas del sector Industria</td>
<td class="text-align-center" style="width: 151px;">17,6</td>
</tr><tr><td style="width: 401px;">2 empresas del sector Energía y Medio Ambiente</td>
<td class="text-align-center" style="width: 151px;">0,7</td>
</tr><tr><td style="width: 401px;">1 empresa de Otros sectores</td>
<td class="text-align-center" style="width: 151px;">0,5</td>
</tr><tr><td class="text-align-right" style="width: 401px;"><strong>Total</strong></td>
<td class="text-align-center" style="width: 151px;"><strong>38,5</strong></td>
</tr></tbody></table><p> </p>
<p>La distribución regional de las empresas en las que se ha aprobado la coinversión es la siguiente:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Comunidad Autónoma</th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de empresas</th>
</tr></thead><tbody><tr><td style="width: 401px;">Andalucía</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">Cataluña</td>
<td class="text-align-center" style="width: 151px;">8</td>
</tr><tr><td style="width: 401px;">Comunidad Valenciana</td>
<td class="text-align-center" style="width: 151px;">3</td>
</tr><tr><td style="width: 401px;">Madrid, Comunidad de</td>
<td class="text-align-center" style="width: 151px;">10</td>
</tr><tr><td style="width: 401px;">Región de Murcia</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr><tr><td style="width: 401px;">País Vasco</td>
<td class="text-align-center" style="width: 151px;">3</td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Con respecto a la fase de desarrollo o madurez de las empresas en las que se ha aprobado la coinversión, se clasifican en:</p>
<table align="center" cellpadding="1" cellspacing="1" style="width: 554px;"><thead><tr><th scope="col" style="width: 401px;">Madurez empresa</th>
<th class="text-align-center" scope="col" style="width: 151px;">Número de empresas</th>
</tr></thead><tbody><tr><td style="width: 401px;">Semilla</td>
<td class="text-align-center" style="width: 151px;">8</td>
</tr><tr><td style="width: 401px;">Arranque</td>
<td class="text-align-center" style="width: 151px;">2</td>
</tr><tr><td style="width: 401px;">Otras fases iniciales</td>
<td class="text-align-center" style="width: 151px;">15</td>
</tr><tr><td style="width: 401px;">Later stage venture</td>
<td class="text-align-center" style="width: 151px;">1</td>
</tr></tbody></table><p> </p>
<p class="text-align-justify">Estas coinversiones se realizarán acompañando a 19 inversores que han sido previamente homologados por Innvierte y que aportarán 45,8 millones de euros.</p>
<p class="text-align-justify">Además de aprobar la coinversión en 26 empresas, en el Consejo de junio se aprobaron dos coinversiones estratégicas (de las cuales una es empresa nueva en Innvierte) con un compromiso de 12,5 millones de euros, lo que supone un compromiso global de 51 millones de euros en inversión directa en empresas.</p>
<p class="text-align-justify">En estos Consejos, se ha aprobado también la homologación de 9 nuevos inversores privados profesionales, por lo que la cifra total de inversores homologados por Innvierte hasta la fecha asciende a 169. De éstos, 122 inversores son activos presentando solicitudes de coinversión a Innvierte.</p>
<h4> </h4>
<h4><strong>Innvierte</strong></h4>
<p class="text-align-justify">Innvierte es una iniciativa cuyo objetivo es promover la innovación empresarial mediante el apoyo a la inversión de capital riesgo en empresas de base tecnológica o innovadoras. Este programa se instrumenta a través de la sociedad de inversión colectiva de tipo cerrado Innvierte Economía Sostenible SICC S.M.E., S.A., auto gestionada y sometida a la supervisión de la Comisión Nacional del Mercado de Valores y de la que el CDTI Innovación, la agencia de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades, es accionista único.</p>
<p class="text-align-justify">Hasta la fecha, el CDTI Innovación, por medio de Innvierte, ha comprometido 1.795 M€ en 42 vehículos de inversión que han invertido en más de 271 empresas, y a través de su línea de coinversión ha comprometido directamente un importe de 522 M€ en 160 empresas.</p>
<p class="text-align-justify">Innvierte se enmarca dentro de la Estrategia Española de Ciencia, Tecnología e Innovación 2021-2027, aprobada por Acuerdo del Consejo de Ministros, en septiembre de 2020. Esta Estrategia contiene los objetivos, las reformas y las medidas que deben adoptarse en todo el ámbito de la I+D+i con el fin de impulsar su crecimiento e impacto, y es uno de los pilares sobre los que se asienta el diseño de la política del Gobierno en I+D+i para los próximos años.</p>
<p> </p>
<h4 class="text-align-justify"><strong>CDTI Innovación</strong></h4>
<p class="text-align-justify">El CDTI Innovación es la entidad pública de financiación de la innovación del Ministerio de Ciencia, Innovación y Universidades que promueve la innovación y el desarrollo tecnológico de las empresas españolas, canalizando las solicitudes de financiación y apoyo a los proyectos de I+D+I de entidades españolas en los ámbitos estatal e internacional. Contribuimos a la mejora del nivel tecnológico de las empresas españolas e impulsamos y, con una red internacional con cobertura de 51 países, acompañamos la participación española en programas internacionales de cooperación tecnológica y la transferencia internacional de su tecnología empresarial. El CDTI también apoya la creación y consolidación de empresas de base tecnológica en España.</p>
<h4 class="text-align-justify"><br /><strong>Más información:</strong></h4>
<p class="text-align-justify">Oficina de Prensa<br /><a href="mailto:prensa@cdti.es" rel="noopener" tabindex="-1" target="_blank">prensa@cdti.es</a><br />
91-581.55.00</p>
<p class="text-align-justify">En Internet<br />
Sitio web: <a href="https://www.cdti.es/noticias/www.cdti.es" previewlistener="true" tabindex="-1">www.cdti.es</a><br />
En LinkedIn: <a href="https://www.linkedin.com/company/29815" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.linkedin.com/company/29815</a><br />
En X: <a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://twitter.com/CDTI_innovacion</a><br />
En YouTube: <a href="https://www.youtube.com/user/CDTIoficial" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">https://www.youtube.com/user/CDTIoficial</a></p>
<p class="text-align-justify">Este contenido es copyright © 2024 CDTI,EPE. Está permitida la utilización y reproducción citando la fuente y la identidad digital de CDTI (<a href="https://twitter.com/CDTI_innovacion" previewlistener="true" rel="noopener" tabindex="-1" target="_blank">@CDTI_innovacion</a>).</p>
</div>
</div>
</div>
</div>
</div></div></description>
<pubDate>Tue, 03 Dec 2024 10:48:44 +0000</pubDate>
<dc:creator>comunicacionsupereditor</dc:creator>
<guid isPermaLink="false">22050 at http://www.cdti.es</guid>
</item>
</channel>
</rss>